Joinn Laboratories (06127) announces its performance in 2024, with a net profit attributable to equity shareholders of 74.075 million yuan, a year-on-year decrease of 81.3%.
Zhao Yan New Medicine (06127) announced its performance in 2024, with revenue of about 2.018 billion yuan, a decrease of 15.1% year-on-year.
Joinn Laboratories (06127) announced its performance for 2024, with revenue of approximately 2.018 billion yuan, a year-on-year decrease of 15.1%; gross profit of approximately 506 million yuan, a year-on-year decrease of 48.4%; net profit attributable to equity shareholders of the company of 74.075 million yuan, a year-on-year decrease of 81.3%; and earnings per share of 0.1 yuan. During the reporting period, the company's overall order backlog amounted to approximately 2.2 billion yuan, with signed orders totaling approximately 1.84 billion yuan.
The announcement stated that the decrease in revenue was mainly driven by increased competition leading to a decline in unit prices for projects.
Related Articles

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


